2022
DOI: 10.1186/s13018-021-02903-7
|View full text |Cite
|
Sign up to set email alerts
|

Anti-high-mobility group box-1 (HMGB1) mediates the apoptosis of alveolar epithelial cells (AEC) by receptor of advanced glycation end-products (RAGE)/c-Jun N-terminal kinase (JNK) pathway in the rats of crush injuries

Abstract: Objectives The lung injury is often secondary to severe trauma. In the model of crush syndrome, there may be secondary lung injury. We hypothesize that high-mobility group box 1 (HMGB1), released from muscle tissue, mediates the apoptosis of alveolar epithelial cells (AEC) via HMGB1/Receptor of advanced glycation end-products (RAGE)/c-Jun N-terminal kinase (JNK) pathway. The study aimed to investigate how HMGB1 mediated the apoptosis of AEC in the rat model. Metho… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0
1

Year Published

2022
2022
2023
2023

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 31 publications
0
1
0
1
Order By: Relevance
“…We noted that the HMGB1 expression in the lung tissues increased in sepsis, which could be decreased by BMSCexos. Most importantly, ML385 successfully blocked the BMSC-exos' role of alleviating the HMGB1 expression in the lung tissues, since HMGB1 expression and secretion could lead to AECII apoptosis and macrophage inflammatory response via its receptor-advanced glycation end products and TLR4 [56,57]. Besides, BMSC-exos successfully alleviated IL-6 levels in BALF serum which could be reversed with ML385.…”
Section: Discussionmentioning
confidence: 98%
“…We noted that the HMGB1 expression in the lung tissues increased in sepsis, which could be decreased by BMSCexos. Most importantly, ML385 successfully blocked the BMSC-exos' role of alleviating the HMGB1 expression in the lung tissues, since HMGB1 expression and secretion could lead to AECII apoptosis and macrophage inflammatory response via its receptor-advanced glycation end products and TLR4 [56,57]. Besides, BMSC-exos successfully alleviated IL-6 levels in BALF serum which could be reversed with ML385.…”
Section: Discussionmentioning
confidence: 98%
“…Щодо ураження легень при СТС, то наявні лише поодинокі клінічні спо стереження ушкодження легень після отриман ня тяжкої травми. Імовірно, ушкодження легень є вторинним відносно травми і зумовлене лейко ци тарною інфільтрацією та підвищенням рівня про запальних цитокінів у легеневій тканині [6,7]…”
unclassified